- Book
- November 2022
- 480 Pages
- Book
- June 2022
- 496 Pages
- Book
- February 2020
- 202 Pages
- Book
- November 2019
- 440 Pages
- Book
- June 2019
- 496 Pages
- Book
- July 2018
- 360 Pages
- Book
- April 2018
- 312 Pages
- Book
- March 2017
- 2008 Pages
- Book
- January 2016
- 472 Pages
- Book
- November 2015
- 776 Pages
- Book
- November 2013
- 744 Pages
- Book
- August 2013
- 386 Pages
- Book
- May 2012
- 528 Pages
- Book
- September 2010
- 984 Pages
- Book
- September 2010
- 484 Pages
- Book
- October 2009
- 912 Pages
- Book
- November 2022
- 300 Pages

The Monoclonal Antibodies market is a subset of the biotechnology industry that focuses on the production and use of monoclonal antibodies (mAbs). mAbs are laboratory-produced proteins that are designed to bind to specific targets, such as proteins, cells, or tissues. They are used in a variety of applications, including diagnostics, therapeutics, and research.
The market for mAbs is growing rapidly, driven by advances in biotechnology and the increasing demand for personalized medicine. mAbs are used in a variety of treatments, including cancer, autoimmune diseases, and infectious diseases. They are also used in research to develop new treatments and to improve existing treatments.
The market for mAbs is highly competitive, with many companies offering a wide range of products. Major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are investing heavily in research and development to develop new mAbs and to improve existing products.
In conclusion, the Monoclonal Antibodies market is an important part of the biotechnology industry, with many companies investing heavily in research and development to develop new products and improve existing treatments. Major players in the market include AbbVie, Amgen, AstraZeneca, Show Less Read more